Announcement • Jun 30
InventisBio Co., Limited to Report First Half, 2026 Results on Aug 21, 2026 InventisBio Co., Limited announced that they will report first half, 2026 results on Aug 21, 2026 Announcement • May 29
InventisBio Co., Limited, Annual General Meeting, Jun 18, 2026 InventisBio Co., Limited, Annual General Meeting, Jun 18, 2026, at 10:00 China Standard Time. Location: No. 63, Lane 1000, Zhangheng Road, Pudong New Area, Shanghai China New Risk • Apr 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CN¥145m net loss in 2 years). Announcement • Apr 16
InventisBio Co., Limited announced that it expects to receive CNY 300 million in funding InventisBio Co., Ltd. announced private placement to issue A shares for gross proceeds of not more than CNY 300,000,000 on April 14, 2026. the transaction includes participation from not more than 35 investors. The issue price not less than 80% of the average price in the 20 trading days before the pricing reference date. The shares cannot be transferred within 6 months from the issuance closing date. The transaction is approved by board of directors of the company in it's 4th Meeting of 2026 of the 2nd Directorate and is subject to approval of shareholders, will be submitted to the Company’s Annual Shareholders Meeting of 2025 for approval. Reported Earnings • Apr 15
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.55 loss per share (further deteriorated from CN¥0.42 loss in FY 2024). Net loss: CN¥316.9m (loss widened 32% from FY 2024). Revenue missed analyst estimates by 74%. Earnings per share (EPS) also missed analyst estimates by 33%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Mar 30
InventisBio Co., Limited to Report Q1, 2026 Results on Apr 29, 2026 InventisBio Co., Limited announced that they will report Q1, 2026 results on Apr 29, 2026 New Risk • Jan 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.9% average weekly change). Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CN¥163m net loss in 2 years). Announcement • Dec 26
InventisBio Co., Limited to Report Fiscal Year 2025 Results on Mar 28, 2026 InventisBio Co., Limited announced that they will report fiscal year 2025 results on Mar 28, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: CN¥0.10 loss per share (vs CN¥0.16 loss in 3Q 2024) Third quarter 2025 results: CN¥0.10 loss per share (improved from CN¥0.16 loss in 3Q 2024). Revenue: CN¥11.7m (up 174% from 3Q 2024). Net loss: CN¥62.0m (loss narrowed 32% from 3Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
InventisBio Co., Limited to Report Q3, 2025 Results on Oct 30, 2025 InventisBio Co., Limited announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 26
Second quarter 2025 earnings released: CN¥0.11 loss per share (vs CN¥0.23 loss in 2Q 2024) Second quarter 2025 results: CN¥0.11 loss per share (improved from CN¥0.23 loss in 2Q 2024). Revenue: CN¥11.0m (up 75% from 2Q 2024). Net loss: CN¥61.9m (loss narrowed 53% from 2Q 2024). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Aug 13
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 107% to CN¥41.03. The fair value is estimated to be CN¥32.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 77% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 130% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. Buy Or Sell Opportunity • Jul 15
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 94% to CN¥38.95. The fair value is estimated to be CN¥32.45, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 77% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 135% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Announcement • Jun 30
InventisBio Co., Limited to Report First Half, 2025 Results on Aug 23, 2025 InventisBio Co., Limited announced that they will report first half, 2025 results on Aug 23, 2025 Buy Or Sell Opportunity • Jun 25
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 80% to CN¥34.25. The fair value is estimated to be CN¥27.82, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 77% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 135% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Buy Or Sell Opportunity • Jun 10
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 104% to CN¥34.20. The fair value is estimated to be CN¥27.82, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 77% over the last 3 years. Earnings per share has grown by 30%. Revenue is forecast to grow by 135% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Announcement • May 30
InventisBio Co., Limited, Annual General Meeting, Jun 20, 2025 InventisBio Co., Limited, Annual General Meeting, Jun 20, 2025, at 09:30 China Standard Time. Major Estimate Revision • May 06
Consensus EPS estimates fall by 26% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -CN¥0.235 to -CN¥0.297 per share. Revenue forecast of CN¥175.0m unchanged since last update. Biotechs industry in China expected to see average net income growth of 29% next year. Consensus price target up from CN¥14.64 to CN¥20.00. Share price rose 5.3% to CN¥22.56 over the past week. Reported Earnings • Apr 27
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: CN¥0.43 loss per share (improved from CN¥0.49 loss in FY 2023). Revenue: CN¥169.1m (down 8.9% from FY 2023). Net loss: CN¥245.6m (loss narrowed 14% from FY 2023). Revenue exceeded analyst estimates by 64%. Earnings per share (EPS) also surpassed analyst estimates by 42%. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 28% growth forecast for the Biotechs industry in China. Announcement • Mar 28
InventisBio Co., Limited to Report Q1, 2025 Results on Apr 29, 2025 InventisBio Co., Limited announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Feb 26
Full year 2024 earnings: EPS and revenues exceed analyst expectations Full year 2024 results: CN¥0.43 loss per share (improved from CN¥0.49 loss in FY 2023). Revenue: CN¥169.1m (down 8.9% from FY 2023). Net loss: CN¥245.6m (loss narrowed 14% from FY 2023). Revenue exceeded analyst estimates by 64%. Earnings per share (EPS) also surpassed analyst estimates by 40%. Revenue is forecast to grow 36% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Biotechs industry in China. Announcement • Dec 27
InventisBio Co., Limited to Report Fiscal Year 2024 Results on Apr 26, 2025 InventisBio Co., Limited announced that they will report fiscal year 2024 results on Apr 26, 2025 Announcement • Dec 03
InventisBio Co., Ltd. Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis InventisBio Co. Ltd. announced promising results from a Phase 2 clinical trial of D-2570, an oral selective inhibitor of the TYK2 kinase, in patients with moderate to severe plaque psoriasis. The randomized, multicenter, double-blind, placebo-controlled study demonstrated that D-2570 achieved significant efficacy in improving skin clearance while maintaining a favorable safety profile. Key Findings: 85% of patients treated with D-2570 in all three dose groups achieved PASI 75 (75% or greater improvement in the Psoriasis Area and Severity Index) by week 12, compared to 12.5% in placebo group. 50% of patients receiving the high dose of D-2570 achieved PASI 100 (complete skin clearance) by week 12, compared To 2.5% in placebo group; PASI 90 and sPGA 0/1 responses also significantly favored D-2570 over placebo, with 77.5% and 87.5%, respectively, in the high-dose group, versus 5.0% and 20%, respectively, in placebo group. The trial enrolled 161 patients randomized to three dose levels of D-2570 or placebo. The primary endpoint of PASI 75 was achieved by a significantly greater proportion of patients in all D-2570 dose groups compared to placebo (p<0.001). Superior efficacy was observed across secondary endpoints, including PASI 90, PASI 100, and static Physician's Global Assessment (sPGA) 0/1. Safety Profile: D-2570 was well-tolerated, with no serious adverse events reported. The majority of adverse events were mild to moderate (CTCAE Grade 1 or 2), and no new safety signals were identified. The safety profile was consistent with other TYK2 inhibitors that are approved or currently in clinical development. The complete data from this Phase 2 trial will be presented at upcoming scientific conferences. New Risk • Nov 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥90m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Major Estimate Revision • Nov 07
Consensus EPS estimates fall by 19% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -CN¥0.537 to -CN¥0.637 per share. Revenue forecast of CN¥155.0m unchanged since last update. Biotechs industry in China expected to see average net income growth of 40% next year. Consensus price target of CN¥14.64 unchanged from last update. Share price rose 8.2% to CN¥11.66 over the past week. Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.16 loss per share (vs CN¥0.13 loss in 3Q 2023) Third quarter 2024 results: CN¥0.16 loss per share (further deteriorated from CN¥0.13 loss in 3Q 2023). Revenue: CN¥4.28m (down 91% from 3Q 2023). Net loss: CN¥91.1m (loss widened 24% from 3Q 2023). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Announcement • Sep 30
InventisBio Co., Limited to Report Q3, 2024 Results on Oct 30, 2024 InventisBio Co., Limited announced that they will report Q3, 2024 results on Oct 30, 2024 New Risk • Sep 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥40m net loss in 2 years). Share price has been volatile over the past 3 months (6.7% average weekly change). Buy Or Sell Opportunity • Sep 27
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to CN¥8.42. The fair value is estimated to be CN¥6.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last year. Earnings per share has grown by 24%. Revenue is forecast to grow by 220% in 2 years. Earnings are forecast to grow by 88% in the next 2 years. Announcement • Jun 28
InventisBio Co., Limited to Report First Half, 2024 Results on Aug 23, 2024 InventisBio Co., Limited announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Jun 02
InventisBio Co., Limited, Annual General Meeting, Jun 21, 2024 InventisBio Co., Limited, Annual General Meeting, Jun 21, 2024, at 10:00 China Standard Time. Buy Or Sell Opportunity • May 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 27% to CN¥8.60. The fair value is estimated to be CN¥10.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 81% in 2 years. Earnings are forecast to grow by 48% in the next 2 years. New Risk • May 01
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.4% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable next year (CN¥352m net loss next year). Announcement • Mar 30
InventisBio Co., Limited to Report Q1, 2024 Results on Apr 30, 2024 InventisBio Co., Limited announced that they will report Q1, 2024 results on Apr 30, 2024 New Risk • Aug 10
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥544m net loss in 2 years). Share price has been volatile over the past 3 months (8.1% average weekly change). New Risk • Jul 18
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 7.1% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥544m net loss in 2 years). Share price has been volatile over the past 3 months (8.0% average weekly change). Announcement • Jun 28
InventisBio Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023 InventisBio Co., Ltd. announced that they will report first half, 2023 results on Aug 22, 2023 
